"Integrated, Multi-'omic' Studies of Asthma Could Lead to Precision Treatment"
Carefully designed, integrated multi-"omic" studies could accelerate the use of precision medicine for asthma patients, according to researchers from the Icahn School of Medicine at Mount Sinai. Scott Tyler, PhD, postdoctoral fellow of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai and Supinda Bunyavanich, MD, MPH, MPhil, associate professor of pediatrics, genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai report that numerous studies have shown the value of applying transcriptomics and other "omic" approaches for defining asthma subtypes—but they also cite the need for more studies aimed at pulling together these disparate data streams for a more comprehensive view of the disease. "Endotypes are important for physicians and biomedical researchers because they organize the way we think about asthma, which manifests in many different ways across patient populations," said Dr. Bunyavanich. Dr. Tyler added, “We are in the early stages of these more sophisticated and comprehensive analyses of asthma, but the growth in available patient cohorts, data repositories, technology, and analytical tools gives us confidence that this kind of approach is rapidly becoming more feasible."
— Scott R. Tyler, PhD, Postdoctoral Fellow, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai
— Supinda Bunyavanich, MD, MPH, Mphil, Associate Professor, Pediatrics, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai